Genzyme Diagnostics (diagnostic intermediates and immunodiagnostics) has acquired privately-held Virotech System Diagnostika (ELISAs for infectious diseases) for approximately $10 million.
Genzyme Corporation has acquired the assets of two European companies. The company's diagnostic division has acquired Virotech System - Diagnostika GmbH, a developer, manufacturer and marketer of in vitro diagnostic kits. Virotech, located in Russelsheim, Germany, specializes in the production of a broad range of Elisa test kits to diagnose infectious diseases. The purchase price was approximately $10 million. The second acquisition, also by Genzyme's diagnostic division, is the business assets of Omnia Res srl, based in Milan, Italy, which specializes in the sales and marketing of immunobiological products. Omnia will form the basis for Genzyme srl, which will also be based in Milan. Terms of the transaction were not disclosed.